Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

PT Kalbe Farma Tbk.

PTKFFPNK
Healthcare
Drug Manufacturers - General
$0.07
$0.00(0.00%)
U.S. Market opens in 8h 18m

PT Kalbe Farma Tbk. Fundamental Analysis

PT Kalbe Farma Tbk. (PTKFF) shows moderate financial fundamentals with a PE ratio of 15.59, profit margin of 10.17%, and ROE of 15.25%. The company generates $34331.0B in annual revenue with moderate year-over-year growth of 7.16%.

Key Strengths

Cash Position129139.05%
PEG Ratio0.00
Current Ratio3.85

Areas of Concern

No major concerns flagged.
We analyze PTKFF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 74.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
74.8/100

We analyze PTKFF's fundamental strength across five key dimensions:

Efficiency Score

Excellent

PTKFF demonstrates superior asset utilization.

ROA > 10%
11.65%

Valuation Score

Excellent

PTKFF trades at attractive valuation levels.

PE < 25
15.59
PEG Ratio < 2
0.00

Growth Score

Excellent

PTKFF delivers strong and consistent growth momentum.

Revenue Growth > 5%
7.16%
EPS Growth > 10%
17.30%

Financial Health Score

Excellent

PTKFF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
3.85

Profitability Score

Moderate

PTKFF maintains healthy but balanced margins.

ROE > 15%
15.25%
Net Margin ≥ 15%
10.17%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is PTKFF Expensive or Cheap?

P/E Ratio

PTKFF trades at 15.59 times earnings. This indicates a fair valuation.

15.59

PEG Ratio

When adjusting for growth, PTKFF's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values PT Kalbe Farma Tbk. at 2.38 times its book value. This may indicate undervaluation.

2.38

EV/EBITDA

Enterprise value stands at 11.29 times EBITDA. This signals the market has high growth expectations.

11.29

How Well Does PTKFF Make Money?

Net Profit Margin

For every $100 in sales, PT Kalbe Farma Tbk. keeps $10.17 as profit after all expenses.

10.17%

Operating Margin

Core operations generate 12.56 in profit for every $100 in revenue, before interest and taxes.

12.56%

ROE

Management delivers $15.25 in profit for every $100 of shareholder equity.

15.25%

ROA

PT Kalbe Farma Tbk. generates $11.65 in profit for every $100 in assets, demonstrating efficient asset deployment.

11.65%

Following the Money - Real Cash Generation

Operating Cash Flow

PT Kalbe Farma Tbk. produces operating cash flow of $3.45T, showing steady but balanced cash generation.

$3.45T

Free Cash Flow

PT Kalbe Farma Tbk. produces free cash flow of $2.71T, offering steady but limited capital for shareholder returns and expansion.

$2.71T

FCF Per Share

Each share generates $59.72 in free cash annually.

$59.72

FCF Yield

PTKFF converts 4.98% of its market value into free cash.

4.98%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

15.59

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.38

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.58

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.85

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.15

vs 25 benchmark

ROA

Return on assets percentage

0.12

vs 25 benchmark

ROCE

Return on capital employed

0.17

vs 25 benchmark

How PTKFF Stacks Against Its Sector Peers

MetricPTKFF ValueSector AveragePerformance
P/E Ratio15.5929.28 Better (Cheaper)
ROE15.25%820.00% Weak
Net Margin10.17%-19731.00% (disorted) Strong
Debt/Equity0.020.26 Strong (Low Leverage)
Current Ratio3.854.69 Strong Liquidity
ROA11.65%-17993.00% (disorted) Strong

PTKFF outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews PT Kalbe Farma Tbk.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

46.31%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

31.20%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

94.03%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ